Jinhe Biotechnology CO., LTD. (SHE:002688)

Market Cap	4.99B
Revenue (ttm)	2.48B
Net Income (ttm)	106.17M
Shares Out	752.11M
EPS (ttm)	0.14
PE Ratio	48.29
Forward PE	27.67
Dividend	0.10 (1.54%)
Ex-Dividend Date	Jun 6, 2025

Volume	100,307,467
Average Volume	70,245,034
Open	6.30
Previous Close	6.50
Day's Range	6.30 - 6.86
52-Week Range	3.40 - 8.69
Beta	0.65
RSI	54.41
Earnings Date	Aug 29, 2025

About SHE:002688

Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin Am...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 2,476
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002688

Financial Performance

In 2024, SHE:002688's revenue was 2.37 billion, an increase of 9.04% compared to the previous year's 2.17 billion. Earnings were 100.20 million, an increase of 15.90%.